All Curated Mutation Sites in SARS-CoV-2

Back to Mutation Home

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in SARS-CoV-2 related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Furin cleavage site

Methyltransferase

Non-coding region

Keyword: COVID-19-35966763

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	35966763	N440K	RBD	S	COVID-19	G	View
2	35966763	N501Y	RBD	S	COVID-19	G	View
3	35966763	Q493K	RBD	S	COVID-19	G	View
4	35966763	S477N	RBD	S	COVID-19	G	View
5	35966763	S500G	RBD	S	COVID-19	G	View
6	35966763	S500T	RBD	S	COVID-19	G	View
7	35966763	T478K	RBD	S	COVID-19	G	View
8	35966763	T500A	RBD	S	COVID-19	G	View
9	35966763	T500C	RBD	S	COVID-19	G	View
10	35966763	T500G	RBD	S	COVID-19	G	View
11	35966763	T500S	RBD	S	COVID-19	G	View
12	35966763	T500T	RBD	S	COVID-19	G	View
13	35966763	Y505H	RBD	S	COVID-19	G	View
14	35966763	E484A	RBD	S	COVID-19		View
15	35966763	G339D	RBD	S	COVID-19		View
16	35966763	G446S	RBD	S	COVID-19		View
17	35966763	G496S	RBD	S	COVID-19		View
18	35966763	K417N	RBD	S	COVID-19		View
19	35966763	Q498R	RBD	S	COVID-19		View
20	35966763	S371L	RBD	S	COVID-19		View
21	35966763	S373P	RBD	S	COVID-19		View
22	35966763	S375F	RBD	S	COVID-19		View

Contents
Description

The table shows all curated mutation sites of SARS-CoV-2 in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.